Stocks · News reference
Over 88% Of Wegovy Trial Participants Achieve Normal Liver Fat Levels, Novo Reports
Novo Nordisk's Wegovy significantly reduced liver fat in adults with obesity in a recent post hoc analysis, potentially lowering MASH risk.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk
Novo's COMPETE SWITCH CV study found that patients who escalated their Ozempic dose to 2 mg had a 6% lower observed risk of major adverse cardiovascular events (MACE) compared to those who switched to Eli Lilly's Mounjaro. However, the study shows association rather than causation and did not evaluate safety outcomes.
Novo Nordisk Says Next-Gen Obesity Drug Reduces Food Noise, Drives Weight Loss
Novo Nordisk presents data showing CagriSema reduces cravings and weight, while real-world patients switching to oral semaglutide also lost weight.